GluN2B protein deficits in the left, but not the right, hippocampus in schizophrenia

BMC Psychiatry

Table 1 Cohort demographic and clinical characteristics

Variable	Cohort	Control	Schizophrenia	t	p
n	Western Blot	20	20
n	Receptor binding	21	20
Age at death	Western Blot	54.5 ± 13.4 (24-73)	54.7 ± 12.8 (27-75)	-0.036	0.971
Mean years ± SD (range)	Receptor binding	55.3 ± 13.1 (24-73)	54.8 ± 12.8 (27-75)	0.132	0.895
Post-mortem interval	Western Blot	28.2 ± 13.3	29.5 ± 12.5	-0.307	0.761
Mean hours ± SD	Receptor binding	30.5 ± 13.6	28.9 ± 12.3	0.388	0.700
pH	Western Blot	6.47 ± 0.35	6.47 ± 0.16	0.069	0.945
Mean ± SD	Receptor binding	6.44 ± 0.35	6.47 ± 0.16	-0.381	0.706
Gender	Western Blot	12 M/8 F	12 M/8 F	N/A	N/A
Gender	Receptor binding	12 M/9 F	12 M/8 F	N/A	N/A
Hemisphere	Western Blot	10 L/10R	11 L/9R	N/A	N/A
Hemisphere	Receptor binding	10 L/11R	10 L/10R	N/A	N/A
Brain weight	Western Blot	1410 ± 128	1358 ± 172	1.085	0.285
Mean grams ± SD	Receptor binding	1396 ± 139	1358 ± 172	0.792	0.433
Estimated daily antipsychotic drug dose	Western Blot	N/A	782 ± 543	N/A	N/A
Mean CPZ equiv ± SD	Receptor binding	N/A	809 ± 529	N/A	N/A
Age of onset	Western Blot	N/A	24.1 ± 8.2 (14-44)	N/A	N/A
Mean years ± SD (range)	Receptor binding	N/A	23.6 ± 8.1 (14-44)	N/A	N/A
Duration of illness	Western Blot	N/A	30.6 ± 11.9 (12-47)	N/A	N/A
Mean years ± SD (range)	Receptor binding	N/A	30.7 ± 11.9 (12-47)	N/A	N/A

There was an overlap of 84% (37/44) between subjects included in the western blot and receptor binding studies. Independent t-tests show no significant differences in age at death, post-mortem interval, pH or brain weight between schizophrenia and control groups; Abbreviations: M, male; F, female; L, left; R, right; PMI, post-mortem interval; CPZ equiv, chlorpromazine equivalents. N/A, not applicable.

ISSN: 1471-244X